27816898|t|Epilepsy in ring chromosome 20 syndrome
27816898|a|Ring chromosome 20 syndrome is characterized by severe, drug resistant childhood onset epilepsy, often accompanied by cognitive impairment. We characterized the electro-clinical phenotype and the long-term course of epilepsy in a large series. We reviewed the electro-clinical phenotype of 25 patients (aged 8-59 years), and assessed the relationship between epilepsy severity and clinical and/or genetic variables. We also searched for reports of patients diagnosed with r(20) syndrome in the literature, included those whose clinical information was sufficiently accurate, and compared their clinical features with the ones of our patients. Epilepsy exhibited an age dependent course. When seizure onset occurred in childhood (21 patients), terrifying hallucinations associated with focal motor seizures, often sleep-related (8 patients), or dyscognitive seizures (13 patients), were prominent features, often evolving into epileptic encephalopathy associated with non-convulsive status epilepticus (11 patients). In the long-term, progressive stabilization of drug resistant epilepsy associated with non-convulsive status epilepticus, focal seizures with motor and autonomic features, and eyelid myoclonia were noticed. Epilepsy onset in adolescence (3 patients) was accompanied by a milder developmental course, dyscognitive seizures and non-convulsive status epilepticus, and no cognitive decline. Only three older patients became seizure free (>5 years) We found statistically significant correlations between age at epilepsy onset and cognitive level. Although in the study cohort the relationship between r(20) ratio, age at epilepsy onset and cognitive level was non-statistically significant, it reached significance evaluating the larger cohort of patients previously published. In ring(20) syndrome, epilepsy has an age dependent course and a worse outcome when age at seizure onset is earlier. The r(20) ratio and severity of cognitive impairment appear to be directly related to each other and inversely correlated with the age at epilepsy onset.
27816898	0	8	Epilepsy	T047	C0014544
27816898	12	39	ring chromosome 20 syndrome	T019	C0265482
27816898	40	67	Ring chromosome 20 syndrome	T019	C0265482
27816898	71	84	characterized	T052	C1880022
27816898	88	94	severe	T080	C0205082
27816898	96	135	drug resistant childhood onset epilepsy	T047	C1096063
27816898	111	135	childhood onset epilepsy	T033	C4315525
27816898	158	178	cognitive impairment	T048	C0338656
27816898	183	196	characterized	T052	C1880022
27816898	201	227	electro-clinical phenotype	T032	C0031437
27816898	236	245	long-term	T079	C0443252
27816898	246	252	course	T079	C0750729
27816898	256	264	epilepsy	T047	C0014544
27816898	270	275	large	T081	C0549177
27816898	276	282	series	T081	C0205549
27816898	287	295	reviewed	T080	C1709940
27816898	300	326	electro-clinical phenotype	T032	C0031437
27816898	333	341	patients	T101	C0030705
27816898	343	347	aged	T032	C0001779
27816898	353	358	years	T079	C0439234
27816898	365	373	assessed	T052	C1516048
27816898	378	390	relationship	T080	C0439849
27816898	399	416	epilepsy severity	T033	C1319803
27816898	421	429	clinical	T033	C1834667
27816898	437	454	genetic variables	T033	C0243095
27816898	464	472	searched	T052	C1706202
27816898	477	496	reports of patients	T170	C0747307
27816898	497	506	diagnosed	T062	C1704656
27816898	512	526	r(20) syndrome	T019	C0265482
27816898	534	544	literature	T170	C0023866
27816898	546	554	included	T169	C0332257
27816898	567	587	clinical information	T170	C2708733
27816898	592	604	sufficiently	T080	C0205410
27816898	605	613	accurate	T080	C0443131
27816898	619	627	compared	T052	C1707455
27816898	634	642	clinical	T080	C0205210
27816898	643	651	features	T080	C2348519
27816898	673	681	patients	T101	C0030705
27816898	683	691	Epilepsy	T047	C0014544
27816898	705	708	age	T032	C0001779
27816898	709	718	dependent	T080	C0851827
27816898	719	725	course	T079	C0750729
27816898	732	745	seizure onset	T033	C0748604
27816898	746	754	occurred	T052	C1709305
27816898	758	767	childhood	T079	C0231335
27816898	772	780	patients	T101	C0030705
27816898	783	793	terrifying	T033	C0558261
27816898	794	808	hallucinations	T048	C0018524
27816898	809	824	associated with	T080	C0332281
27816898	825	845	focal motor seizures	T047	C0016399
27816898	853	866	sleep-related	T047	C2875121
27816898	870	878	patients	T101	C0030705
27816898	884	905	dyscognitive seizures	T033	C4013600
27816898	910	918	patients	T101	C0030705
27816898	926	944	prominent features	T080	C2348519
27816898	966	990	epileptic encephalopathy	T047	C0543888
27816898	991	1006	associated with	T080	C0332281
27816898	1007	1040	non-convulsive status epilepticus	T047	C0751523
27816898	1045	1053	patients	T101	C0030705
27816898	1063	1072	long-term	T079	C0443252
27816898	1074	1085	progressive	T169	C0205329
27816898	1086	1099	stabilization	T061	C1293130
27816898	1103	1126	drug resistant epilepsy	T047	C1096063
27816898	1127	1142	associated with	T080	C0332281
27816898	1143	1176	non-convulsive status epilepticus	T047	C0751523
27816898	1178	1192	focal seizures	T184	C0751495
27816898	1198	1203	motor	T201	C1285624
27816898	1208	1226	autonomic features	T033	C2674101
27816898	1232	1248	eyelid myoclonia	T047	C0014550
27816898	1263	1271	Epilepsy	T047	C0014544
27816898	1272	1277	onset	T080	C0332162
27816898	1281	1292	adolescence	T079	C0001578
27816898	1296	1304	patients	T101	C0030705
27816898	1327	1333	milder	T080	C2945599
27816898	1334	1347	developmental	T080	C0458003
27816898	1348	1354	course	T079	C0750729
27816898	1356	1377	dyscognitive seizures	T033	C4013600
27816898	1382	1415	non-convulsive status epilepticus	T047	C0751523
27816898	1421	1441	no cognitive decline	T033	C2749513
27816898	1448	1453	three	T081	C0205449
27816898	1454	1468	older patients	T101	C0030705
27816898	1476	1488	seizure free	T033	C1299590
27816898	1493	1498	years	T079	C0439234
27816898	1509	1534	statistically significant	T081	C0237881
27816898	1535	1547	correlations	T080	C1707520
27816898	1556	1559	age	T032	C0001779
27816898	1563	1571	epilepsy	T047	C0014544
27816898	1572	1577	onset	T080	C0332162
27816898	1582	1597	cognitive level	T041	C0392335
27816898	1615	1627	study cohort	T081	C0009247
27816898	1632	1644	relationship	T080	C0439849
27816898	1653	1664	r(20) ratio	T081	C0456603
27816898	1666	1669	age	T032	C0001779
27816898	1673	1681	epilepsy	T047	C0014544
27816898	1682	1687	onset	T080	C0332162
27816898	1692	1707	cognitive level	T041	C0392335
27816898	1712	1741	non-statistically significant	T033	C1273937
27816898	1754	1766	significance	T078	C0750502
27816898	1767	1777	evaluating	T058	C0220825
27816898	1782	1788	larger	T081	C0549177
27816898	1789	1795	cohort	T098	C0599755
27816898	1799	1807	patients	T101	C0030705
27816898	1808	1818	previously	T079	C0205156
27816898	1819	1828	published	T170	C0993637
27816898	1833	1850	ring(20) syndrome	T019	C0265482
27816898	1852	1860	epilepsy	T047	C0014544
27816898	1868	1871	age	T032	C0001779
27816898	1872	1881	dependent	T080	C1701901
27816898	1882	1888	course	T079	C0750729
27816898	1895	1900	worse	T033	C1457868
27816898	1901	1908	outcome	T169	C1274040
27816898	1914	1917	age	T032	C0001779
27816898	1921	1934	seizure onset	T033	C0748604
27816898	1951	1962	r(20) ratio	T081	C0456603
27816898	1967	1975	severity	T080	C0439793
27816898	1979	1999	cognitive impairment	T048	C0338656
27816898	2013	2021	directly	T080	C1947931
27816898	2022	2029	related	T080	C0439849
27816898	2048	2057	inversely	T080	C0439850
27816898	2058	2068	correlated	T080	C1707520
27816898	2078	2081	age	T032	C0001779
27816898	2085	2093	epilepsy	T047	C0014544
27816898	2094	2099	onset	T080	C0332162